
|Articles|December 8, 2008
LEO Pharma establishes company in China
Shanghai, China - LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.
Advertisement
Shanghai, China
- LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.
LEO Pharma China, the new company, will market Daivobet, LEO Pharma's psoriasis brand, which was recently approved by the Chinese authorities in order to market the drug in China.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















